USABiotech & Genomic Medicine▲
Congestive Heart Failure Market to Grow at 8% CAGR Through 2036, Reaching USD 9 Billion in 2025
The congestive heart failure market across the seven major markets was valued at USD 9 billion in 2025 and is projected to grow at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the 7MM market in 2025, with nearly 7.4 million diagnosed prevalent cases out of approximately 21.1 million total diagnosed prevalent cases across the seven major markets. Growth is expected to be driven by the rising prevalence of cardiovascular diseases, an aging population, and the anticipated launch of emerging therapies such as Omecamtiv Mecarbil from Cytokinetics, Ziltivekimab from Novo Nordisk, CardiALLO Cell Therapy from BioCardia, and Umiposgene Parvec from Bayer. The report also highlights a robust clinical pipeline that includes candidates from AstraZeneca, Boehringer Ingelheim, Mesoblast, and AskBio, among others.
About megatrends
Biotech & Genomic Medicine › Cardiovascular & Heart-Failure Therapeutics ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Aging Population › Medical Devices for the Aging Body ▲Demand
CYTK · Technology · Positive Omecamtiv Mecarbil from Cytokinetics is mentioned as an emerging therapy expected to drive market growth.
BCDA · Technology · Positive CardiALLO Cell Therapy from BioCardia is highlighted as an emerging therapy expected to drive market growth.
NVO · Technology · Positive Ziltivekimab from Novo Nordisk is mentioned as an emerging therapy expected to drive market growth.
BAYN.XETRA · Technology · Positive Umiposgene Parvec from Bayer is highlighted as an emerging therapy expected to drive market growth.
AZN.LSE · Technology · Positive AstraZeneca is noted as having a candidate in the robust clinical pipeline for congestive heart failure.
AskBio (Asklepios BioPharmaceutical, Inc.) · Demand · Positive Mentioned as having a candidate in the robust clinical pipeline for congestive heart failure, indicating potential future market opportunity.